Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Roth Capital

Roth Capital upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a strong-buy rating in a research note published on Friday,Zacks.com reports.

A number of other research analysts also recently commented on the stock. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Friday. EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd. Finally, Roth Mkm began coverage on Reviva Pharmaceuticals in a report on Friday. They issued a “buy” rating and a $7.00 price objective on the stock. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $11.25.

Reviva Pharmaceuticals Stock Performance

Shares of Reviva Pharmaceuticals stock opened at $1.88 on Friday. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $4.83. The company has a fifty day moving average of $1.56 and a 200 day moving average of $1.29. The company has a market capitalization of $62.87 million, a P/E ratio of -1.69 and a beta of -0.12.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the period. Geode Capital Management LLC owned approximately 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.